STAT+: Pharmalittle: CVS whistleblower suit details plans to boost consumer drug costs; Roche reports negative Alzheimer’s trial results

Hello, everyone, and how are you today? Another dank cloudy cover greeted us this morning, but we are ignoring the gloom by keeping busy. After all, there is much to be done. There are deadlines to meet, a variety of reading materials to digest, and calls to make. We trust you can relate. So please join us as we fortify ourselves with more cups of stimulation — we are back to wild mountain blueberry — and get started. Hope you conquer the world and accomplish much. And of course, be in touch. We cherish your postcards and telegrams. …

Starting in 2015, a whistleblower lawsuit alleged CVS Health coordinated an effort that relied on its SilverScript subsidiary, its Caremark pharmacy benefits manager, and its chain of CVS retail pharmacies to prevent consumers from obtaining low-cost generics because the company profited from making only higher-priced brand-name medicines available to its customers, STAT reports. The scheme involved arrangements with drug companies that allegedly sought to block generic competition for more than a dozen widely prescribed, brand-name medicines. Medicare Part D beneficiaries were forced to pay more than they would have otherwise if lower-cost generics were available on a formulary.

Continue to STAT+ to read the full story…